{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:05:19Z","timestamp":1790013919920,"version":"4.0.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004748","name":"Mashhad University of Medical Sciences","doi-asserted-by":"publisher","award":["981622"],"award-info":[{"award-number":["981622"]}],"id":[{"id":"10.13039\/501100004748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s11095-026-04141-0","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T21:04:47Z","timestamp":1782335087000},"page":"2775-2793","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Injectable in-situ Forming Lipid Liquid Crystal for Long-acting Fluocinolone Release in Posterior Ocular Therapy: In-vitro and In-vivo Evaluations"],"prefix":"10.1007","volume":"43","author":[{"given":"Malihe","family":"Karimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojtaba","family":"Abrishami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Farzadnia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Kamali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1908-9530","authenticated-orcid":false,"given":"Bizhan","family":"Malaekeh-Nikouei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"key":"4141_CR1","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1136\/bjophthalmol-2020-315984","volume":"105","author":"SE Mansour","year":"2021","unstructured":"Mansour SE, Kiernan DF, Roth DB, Eichenbaum D, Holekamp NM, Kaba S, et al. Two-year interim safety results of the 0.2 \u00b5g\/day fluocinolone acetonide intravitreal implant for the treatment of diabetic macular oedema: the observational PALADIN study. Br J Ophthalmol. 2021;105:414\u20139.","journal-title":"Br J Ophthalmol"},{"key":"4141_CR2","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ijpharm.2018.07.013","volume":"548","author":"C Bode","year":"2018","unstructured":"Bode C, Kranz H, Siepmann F, Siepmann J. In-situ forming PLGA implants for intraocular dexamethasone delivery. Int J Pharm. 2018;548:337\u201348.","journal-title":"Int J Pharm"},{"key":"4141_CR3","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jconrel.2023.07.055","volume":"361","author":"Q Qi","year":"2023","unstructured":"Qi Q, Wei Y, Zhang X, Guan J, Mao S. Challenges and strategies for ocular posterior diseases therapy via non-invasive advanced drug delivery. J Control Release. 2023;361:191\u2013211.","journal-title":"J Control Release"},{"key":"4141_CR4","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.jconrel.2014.05.031","volume":"193","author":"IP Kaur","year":"2014","unstructured":"Kaur IP, Kakkar S. Nanotherapy for posterior eye diseases. J Control Release. 2014;193:100\u201312.","journal-title":"J Control Release"},{"key":"4141_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114342","volume":"187","author":"RA Alshaikh","year":"2022","unstructured":"Alshaikh RA, Waeber C, Ryan KB. Polymer based sustained drug delivery to the ocular posterior segment: barriers and future opportunities for the treatment of neovascular pathologies. Adv Drug Deliv Rev. 2022;187:114342.","journal-title":"Adv Drug Deliv Rev"},{"key":"4141_CR6","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.jconrel.2020.07.031","volume":"326","author":"BC Ilochonwu","year":"2020","unstructured":"Ilochonwu BC, Urtti A, Hennink WE, Vermonden T. Intravitreal hydrogels for sustained release of therapeutic proteins. J Control Release. 2020;326:419\u201341.","journal-title":"J Control Release"},{"key":"4141_CR7","first-page":"16","volume":"3","author":"T Rani","year":"2012","unstructured":"Rani T, Mohit S. An insight to ophthalmic in situ gel: an overview. Int Res J Pharm. 2012;3:16\u201321.","journal-title":"Int Res J Pharm"},{"key":"4141_CR8","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jddst.2017.06.006","volume":"40","author":"R Bisht","year":"2017","unstructured":"Bisht R, Jaiswal JK, Oliver VF, Eurtivong C, Reynisson J, Rupenthal ID. Preparation and evaluation of PLGA nanoparticle-loaded biodegradable light-responsive injectable implants as a promising platform for intravitreal drug delivery. J Drug Deliv Sci Technol. 2017;40:142\u201356.","journal-title":"J Drug Deliv Sci Technol"},{"key":"4141_CR9","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/j.addr.2006.07.027","volume":"58","author":"A Urtti","year":"2006","unstructured":"Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev. 2006;58:1131\u20135.","journal-title":"Adv Drug Deliv Rev"},{"key":"4141_CR10","doi-asserted-by":"publisher","first-page":"621","DOI":"10.4155\/tde-2019-0051","volume":"10","author":"I Testi","year":"2019","unstructured":"Testi I, Pavesio C. Preliminary evaluation of YUTIQ\u2122(fluocinolone acetonide intravitreal implant 0.18 mg) in posterior uveitis. Ther Deliv. 2019;10:621\u20135.","journal-title":"Ther Deliv"},{"key":"4141_CR11","first-page":"317","volume":"6","author":"N Haghjou","year":"2011","unstructured":"Haghjou N, Soheilian M, Abdekhodaie MJ. Sustained release intraocular drug delivery devices for treatment of uveitis. J Ophthalmic Vis Res. 2011;6:317.","journal-title":"J Ophthalmic Vis Res"},{"key":"4141_CR12","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1089\/1080768041223611","volume":"20","author":"J-Y Driot","year":"2004","unstructured":"Driot J-Y, Novack GD, Rittenhouse KD, Milazzo C, Pearson AP. Ocular pharmacokinetics of fluocinolone acetonide after Retisert\u2122 intravitreal implantation in rabbits over a 1-year period. J Ocul Pharmacol Ther. 2004;20:269\u201375.","journal-title":"J Ocul Pharmacol Ther"},{"key":"4141_CR13","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40265-017-0722-4","volume":"77","author":"YY Syed","year":"2017","unstructured":"Syed YY. Fluocinolone acetonide intravitreal implant 0.19 mg (ILUVIEN\u00ae): a review in diabetic macular edema. Drugs. 2017;77:575\u201383.","journal-title":"Drugs"},{"key":"4141_CR14","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jconrel.2014.09.030","volume":"196","author":"MN Yasin","year":"2014","unstructured":"Yasin MN, Svirskis D, Seyfoddin A, Rupenthal ID. Implants for drug delivery to the posterior segment of the eye: a focus on stimuli-responsive and tunable release systems. J Control Release. 2014;196:208\u201321.","journal-title":"J Control Release"},{"key":"4141_CR15","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s13346-021-01043-z","volume":"12","author":"MF Adrianto","year":"2022","unstructured":"Adrianto MF, Annuryanti F, Wilson CG, Sheshala R, Thakur RRS. In vitro dissolution testing models of ocular implants for posterior segment drug delivery. Drug Deliv Transl Res. 2022;12:1355\u201375.","journal-title":"Drug Deliv Transl Res"},{"key":"4141_CR16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jconrel.2017.07.035","volume":"268","author":"L Lalu","year":"2017","unstructured":"Lalu L, Tambe V, Pradhan D, Nayak K, Bagchi S, Maheshwari R, et al. Novel nanosystems for the treatment of ocular inflammation: current paradigms and future research directions. J Control Release. 2017;268:19\u201339.","journal-title":"J Control Release"},{"key":"4141_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15071862","volume":"15","author":"A Gabai","year":"2023","unstructured":"Gabai A, Zeppieri M, Finocchio L, Salati C. Innovative strategies for drug delivery to the ocular posterior segment. Pharmaceutics. 2023;15:1862.","journal-title":"Pharmaceutics"},{"key":"4141_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.123973","volume":"654","author":"M Karimi","year":"2024","unstructured":"Karimi M, Abrishami M, Farzadnia M, Kamali H, Malaekeh-Nikouei B. In-situ forming biodegradable implants for sustained fluocinolone acetonide release to the posterior eye: in-vitro and in-vivo investigations in rabbits. Int J Pharm. 2024;654:123973.","journal-title":"Int J Pharm"},{"key":"4141_CR19","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1080\/14737140.2022.2082947","volume":"22","author":"AS Merseburger","year":"2022","unstructured":"Merseburger AS, Roesch MC. Advanced delivery of leuprorelin acetate for the treatment of prostatic cancer. Expert Rev Anticancer Ther. 2022;22:703\u201315.","journal-title":"Expert Rev Anticancer Ther"},{"key":"4141_CR20","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.ijpharm.2017.08.098","volume":"532","author":"A Otte","year":"2017","unstructured":"Otte A, B\u00e1ez-Santos YM, Mun EA, Soh B-K, Lee Y-n, Park K. The in vivo transformation and pharmacokinetic properties of a liquid crystalline drug delivery system. Int J Pharm. 2017;532:345\u201351.","journal-title":"Int J Pharm"},{"key":"4141_CR21","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.actbio.2019.09.011","volume":"99","author":"B Wang","year":"2019","unstructured":"Wang B, Huang Y, Huang Z, Wang H, Chen J, Pan X, et al. Self-assembling in situ gel based on lyotropic liquid crystals containing VEGF for tissue regeneration. Acta Biomater. 2019;99:84\u201399.","journal-title":"Acta Biomater"},{"key":"4141_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40005-014-0165-9","volume":"45","author":"D-H Kim","year":"2015","unstructured":"Kim D-H, Jahn A, Cho S-J, Kim JS, Ki M-H, Kim D-D. Lyotropic liquid crystal systems in drug delivery: a review. J Pharm Investig. 2015;45:1\u201311.","journal-title":"J Pharm Investig"},{"key":"4141_CR23","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.drudis.2010.09.006","volume":"15","author":"C Guo","year":"2010","unstructured":"Guo C, Wang J, Cao F, Lee RJ, Zhai G. Lyotropic liquid crystal systems in drug delivery. Drug Discov Today. 2010;15:1032\u201340.","journal-title":"Drug Discov Today"},{"key":"4141_CR24","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jconrel.2014.04.034","volume":"185","author":"MH Ki","year":"2014","unstructured":"Ki MH, Lim JL, Ko JY, Park SH, Kim JE, Cho HJ, et al. A new injectable liquid crystal system for one month delivery of leuprolide. J Control Release. 2014;185:62\u201370.","journal-title":"J Control Release"},{"key":"4141_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.121275","volume":"611","author":"H Kamali","year":"2022","unstructured":"Kamali H, Karimi M, Abbaspour M, Nadim A, Hadizadeh F, Khodaverdi E, et al. Comparison of lipid liquid crystal formulation and Vivitrol\u00ae for sustained release of naltrexone: in vitro evaluation and pharmacokinetics in rats. Int J Pharm. 2022;611:121275.","journal-title":"Int J Pharm"},{"key":"4141_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2024.105640","author":"M Karimi","year":"2024","unstructured":"Karimi M, Azimi-Hashemi S, Khodaverdi E, Mohammadi M, Eisvand F, Rahbardar-Khorasani A, et al. Preparation and characterization of injectable in-situ forming gel based on lipid liquid crystal for one month delivery of aripiprazole: in-vitro and in-vivo evaluations in rats. J Drug Deliv Sci Technol. 2024. https:\/\/doi.org\/10.1016\/j.jddst.2024.105640.","journal-title":"J Drug Deliv Sci Technol"},{"key":"4141_CR27","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.ijpharm.2015.05.049","volume":"490","author":"J-L Lim","year":"2015","unstructured":"Lim J-L, Ki M-H, Joo MK, An S-W, Hwang K-M, Park E-S. An injectable liquid crystal system for sustained delivery of entecavir. Int J Pharm. 2015;490:265\u201372.","journal-title":"Int J Pharm"},{"key":"4141_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2023.122947","volume":"639","author":"M Karimi","year":"2023","unstructured":"Karimi M, Kamali H, Fakhrmohammadi S, Khezri E, Malaekeh-Nikouei B, Mohammadi M. Prolonged local delivery of doxorubicin to cancer cells using lipid liquid crystalline system. Int J Pharm. 2023;639:122947.","journal-title":"Int J Pharm"},{"key":"4141_CR29","unstructured":"Svenska E, Pedroncelli AM. Camurus receives EU approval for weekly and monthly Buvidal\u00ae(CAM2038) for opioid dependence. Camurus [Internet]. 2018 [cited 2026 Jun 20]. Available from: https:\/\/news.cision.com\/camurus-ab\/r\/camurus-receives-eu-approval-for-weekly-and-monthly-buvidal---cam2038--for-opioid-dependence,c2680050."},{"key":"4141_CR30","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1080\/10717544.2019.1667451","volume":"26","author":"W Xingqi","year":"2019","unstructured":"Xingqi W, Yong Z, Xing L, Yang W, Jie H, Rongfeng H, et al. Cubic and hexagonal liquid crystal gels for ocular delivery with enhanced effect of pilocarpine nitrate on anti-glaucoma treatment. Drug Deliv. 2019;26:952\u201364.","journal-title":"Drug Deliv"},{"key":"4141_CR31","doi-asserted-by":"publisher","first-page":"204","DOI":"10.7324\/JAPS.2016.60930","volume":"6","author":"Z Ali","year":"2016","unstructured":"Ali Z, Sharma PK, Warsi MH. Fabrication and evaluation of ketorolac loaded cubosome for ocular drug delivery. J Appl Pharm Sci. 2016;6:204\u20138.","journal-title":"J Appl Pharm Sci"},{"key":"4141_CR32","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ijpharm.2010.06.015","volume":"396","author":"L Gan","year":"2010","unstructured":"Gan L, Han S, Shen J, Zhu J, Zhu C, Zhang X, et al. Self-assembled liquid crystalline nanoparticles as a novel ophthalmic delivery system for dexamethasone: improving preocular retention and ocular bioavailability. Int J Pharm. 2010;396:179\u201387.","journal-title":"Int J Pharm"},{"key":"4141_CR33","unstructured":"Malaekeh-Nikouei B, Vafaei F, Karimi M, Nosrati R, Kamali H. Preparation and in-vitro evaluation of fluorometholone cubosomes for ocular delivery. Nanomed J. 2023;10(4):304\u201312."},{"key":"4141_CR34","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1208\/s12249-017-0763-8","volume":"18","author":"J Huang","year":"2017","unstructured":"Huang J, Peng T, Li Y, Zhan Z, Zeng Y, Huang Y, et al. Ocular cubosome drug delivery system for timolol maleate: preparation, characterization, cytotoxicity, ex vivo, and in vivo evaluation. AAPS PharmSciTech. 2017;18:2919\u201326.","journal-title":"AAPS PharmSciTech"},{"key":"4141_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2021.105748","volume":"160","author":"CDV Bessone","year":"2021","unstructured":"Bessone CDV, Akhlaghi SP, T\u00e1rtara LI, Quinteros DA, Loh W, Allemandi DA. Latanoprost-loaded phytantriol cubosomes for the treatment of glaucoma. Eur J Pharm Sci. 2021;160:105748.","journal-title":"Eur J Pharm Sci"},{"key":"4141_CR36","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1038\/aps.2010.98","volume":"31","author":"S Han","year":"2010","unstructured":"Han S, Shen J-q, Gan Y, Geng H-m, Zhang X-x, Zhu C-l, et al. Novel vehicle based on cubosomes for ophthalmic delivery of flurbiprofen with low irritancy and high bioavailability. Acta Pharmacol Sin. 2010;31:990\u20138.","journal-title":"Acta Pharmacol Sin"},{"key":"4141_CR37","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.ejpb.2019.04.009","volume":"139","author":"S Milak","year":"2019","unstructured":"Milak S, Chemelli A, Glatter O, Zimmer A. Vancomycin ocular delivery systems based on glycerol monooleate reversed hexagonal and reversed cubic liquid crystalline phases. Eur J Pharm Biopharm. 2019;139:279\u201390.","journal-title":"Eur J Pharm Biopharm"},{"key":"4141_CR38","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/S1773-2247(13)50049-9","volume":"23","author":"A Yaghmur","year":"2013","unstructured":"Yaghmur A, Rappolt M, Larsen S. In situ forming drug delivery systems based on lyotropic liquid crystalline phases: structural characterization and release properties. J Drug Deliv Sci Technol. 2013;23:325\u201332.","journal-title":"J Drug Deliv Sci Technol"},{"key":"4141_CR39","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1089\/jop.2014.0082","volume":"30","author":"R Bhagat","year":"2014","unstructured":"Bhagat R, Zhang J, Farooq S, Li X-Y. Comparison of the release profile and pharmacokinetics of intact and fragmented dexamethasone intravitreal implants in rabbit eyes. J Ocul Pharmacol Ther. 2014;30:854\u20138.","journal-title":"J Ocul Pharmacol Ther"},{"key":"4141_CR40","first-page":"395","volume":"40","author":"N Lipman","year":"1990","unstructured":"Lipman N, Marini R, Erdman S. A comparison of ketamine\/xylazine and ketamine\/xylazine\/acepromazine anesthesia in the rabbit. Lab Anim Sci. 1990;40:395\u20138.","journal-title":"Lab Anim Sci"},{"key":"4141_CR41","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3928\/23258160-20191119-06","volume":"50","author":"A Lashay","year":"2019","unstructured":"Lashay A, Delrish E, Ashrafi E, Movassat M, Asadi-Amoli F, Dinarvand R, et al. Safety and bioavailability of complete and half-dose intravitreal ziv-aflibercept in an experimental model: contralateral eye study. Ophthalmic Surg Lasers Imaging Retina. 2019;50:785\u201390.","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"4141_CR42","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0378-5173(02)00375-7","volume":"246","author":"S Fitzpatrick","year":"2002","unstructured":"Fitzpatrick S, McCabe JF, Petts CR, Booth SW. Effect of moisture on polyvinylpyrrolidone in accelerated stability testing. Int J Pharm. 2002;246:143\u201351.","journal-title":"Int J Pharm"},{"key":"4141_CR43","unstructured":"Tiberg F, Joabsson F. Lipid liquid crystals for parenteral sustained-release applications: combining ease of use and manufacturing with consistent drug release control. Injectable Drug Deliv. 2010;9\u201312."},{"key":"4141_CR44","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.ijpharm.2016.06.138","volume":"514","author":"YM B\u00e1ez-Santos","year":"2016","unstructured":"B\u00e1ez-Santos YM, Otte A, Mun EA, Soh B-K, Song C-G, Lee Y-n, et al. Formulation and characterization of a liquid crystalline hexagonal mesophase region of phosphatidylcholine, sorbitan monooleate, and tocopherol acetate for sustained delivery of leuprolide acetate. Int J Pharm. 2016;514:314\u201321.","journal-title":"Int J Pharm"},{"key":"4141_CR45","doi-asserted-by":"publisher","first-page":"547","DOI":"10.4155\/tde-2018-0006","volume":"9","author":"MS Habib","year":"2018","unstructured":"Habib MS. ILUVIEN\u00ae technology in the treatment of center-involving diabetic macular edema: a review of the literature. Ther Deliv. 2018;9:547\u201356.","journal-title":"Ther Deliv"},{"key":"4141_CR46","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1089\/jop.2014.0100","volume":"31","author":"FE Kane","year":"2015","unstructured":"Kane FE, Green KE. Ocular pharmacokinetics of fluocinolone acetonide following Iluvien implantation in the vitreous humor of rabbits. J Ocul Pharmacol Ther. 2015;31:11\u20136.","journal-title":"J Ocul Pharmacol Ther"},{"key":"4141_CR47","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.ophtha.2012.09.014","volume":"120","author":"PA Campochiaro","year":"2013","unstructured":"Campochiaro PA, Nguyen QD, Hafiz G, Bloom S, Brown DM, Busquets M, et al. Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants. Ophthalmology. 2013;120:583\u20137.","journal-title":"Ophthalmology"},{"key":"4141_CR48","unstructured":"Kiss S. Sustained-release corticosteroid delivery systems. Retina Today. 2010;44\u20136."},{"key":"4141_CR49","doi-asserted-by":"publisher","first-page":"4826","DOI":"10.1021\/bi00339a017","volume":"24","author":"M Caffrey","year":"1985","unstructured":"Caffrey M. Kinetics and mechanisms of the lamellar gel\/lamellar liquid-crystal and lamellar\/inverted hexagonal phase transition in phosphatidylethanolamine: a real-time X-ray diffraction study using synchrotron radiation. Biochemistry. 1985;24:4826\u201344.","journal-title":"Biochemistry"},{"key":"4141_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12060567","volume":"12","author":"L Rahnfeld","year":"2020","unstructured":"Rahnfeld L, Luciani P. Injectable lipid-based depot formulations: where do we stand? Pharmaceutics. 2020;12:567.","journal-title":"Pharmaceutics"},{"key":"4141_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2023.114901","volume":"199","author":"R Sharma","year":"2023","unstructured":"Sharma R, Yadav S, Yadav V, Akhtar J, Katari O, Kuche K, et al. Recent advances in lipid-based long-acting injectable depot formulations. Adv Drug Deliv Rev. 2023;199:114901.","journal-title":"Adv Drug Deliv Rev"},{"issue":"6","key":"4141_CR52","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1097\/ADM.0000000000001484","volume":"19","author":"MR Lofwall","year":"2025","unstructured":"Lofwall MR, Nunes EV, Walsh SL, Bailey GL, Frost M, Budilovsky-Kelley NR, et al. Dosing to effect with weekly and monthly subcutaneous and daily sublingual buprenorphine: post hoc analysis of a phase 3 clinical trial. J Addict Med. 2025;19(6):676\u201384.","journal-title":"J Addict Med."},{"key":"4141_CR53","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1016\/j.drudis.2019.02.001","volume":"24","author":"A Subrizi","year":"2019","unstructured":"Subrizi A, Del Amo EM, Korzhikov-Vlakh V, Tennikova T, Ruponen M, Urtti A. Design principles of ocular drug delivery systems: importance of drug payload, release rate, and material properties. Drug Discov Today. 2019;24:1446\u201357.","journal-title":"Drug Discov Today"},{"key":"4141_CR54","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1016\/S0161-6420(00)00466-8","volume":"107","author":"GJ Jaffe","year":"2000","unstructured":"Jaffe GJ, Ben-nun J, Guo H, Dunn JP, Ashton P. Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmology. 2000;107:2024\u201333.","journal-title":"Ophthalmology"},{"key":"4141_CR55","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/0892-0362(94)90045-0","volume":"16","author":"U Hass","year":"1994","unstructured":"Hass U, Lund SP, Elsner J. Effects of prenatal exposure to N-methylpyrrolidone on postnatal development and behavior in rats. Neurotoxicol Teratol. 1994;16:241\u20139.","journal-title":"Neurotoxicol Teratol"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04141-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-026-04141-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04141-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:02:23Z","timestamp":1790010143000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-026-04141-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":55,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["4141"],"URL":"https:\/\/doi.org\/10.1007\/s11095-026-04141-0","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]},"assertion":[{"value":"20 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study received ethical approval from the Animal Experimentation Ethics Committee at Mashhad University in Iran, referenced under the ethical approval code IR. MUMS.PHARMACY.1398.117.","order":1,"name":"Ethics","label":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors confirm that there are no conflicts of interest to disclose.","order":2,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}